Australia's CSL (CSL.AX) on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
Its Behring division was hurt by pricing pressure in the U.S. market and the implementation of government cost-control policies in China.
Total revenue at CSL Behring, which develops medicines to treat bleeding disorders and immune deficiencies, among others, fell 1% to $11.4 billion.
Sales of immunoglobulin product were flat, while those of albumin dropped 17%.
The company recognised pre-tax impairments of $5.5 billion in the second half of full-year 2026, bringing its total pre-tax impairments to $7.1 billion in the fiscal.
It also incurred one-off pre-tax restructuring costs of $799 million. That brought its net loss after tax to $2.6 billion, compared with a profit of $3 billion last year.
CSL declared a final dividend of $1.62 per share, unchanged from last year.
The company, among the world's top flu vaccine makers, reported underlying net profit after tax attributable of $3.14 billion on a constant currency basis for the year ended June 30, compared with $3.22 billion last year.
